February 9, 2011 – The first patients have been enrolled in a trial investigating the safety and efficacy of a system that removes clot from acute ischemic stroke patients. The Trevo 2 study will look at the Trevo Retriever device, from Concentric Medical.
It is the first device to use Stentriever technology for retrieving clots from the neurovasculature.
The patients were enrolled at Oregon Health and Science University in Portland, Ore., and at Capital Health in Trenton, N.J.
"The continued advancement of retrieval devices is critical to our abilities to treat stroke patients," said Erol Veznedaroglu, M.D., director of neurosciences and cerebrovascular and endovascular neurosurgery at Capital Health. The device was used for the first time in the United States by Kenneth Liebman, M.D., at Capital Health.
"The experience with Stentriever devices in Europe is very encouraging. We expect the Trevo Retriever to be more effective and to treat patients more quickly and ultimately expand endovascular treatment to more stroke patients in years to come," Liebman said.
The device is the first and only retriever of its type designed for quick access, rapid clot integration and predictable clot retrieval in ischemic stroke patients.
The TREVO 2 study will build upon the company’s previous clot retrieval trials, Merci and Multi Merci. Both have provided compelling evidence of the benefits of retrieving stroke-causing clots from the blood vessels of acute ischemic stroke patients.
For more information: www.concentric-medical.com